Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zomedica Pharmaceuticals Corp (NY: ZOM )

0.1380 +0.0080 (+6.15%)
Official Closing Price Updated: 4:10 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,476,498
Open 0.1320
Bid (Size) 0.1316 (52)
Ask (Size) 0.1341 (5)
Prev. Close 0.1300
Today's Range 0.1303 - 0.1380
52wk Range 0.1200 - 0.2285
Shares Outstanding 979,949,668
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zomedica Strengthens European Foothold With Grovet Partnership, Expanding PulseVet And TRUFORMA Reach
Zomedica expands partnership with Grovet to distribute equine products in 27 European countries, including Germany, France, and Spain. 
Via Benzinga
Zomedica Announces Expansion of Exclusive Equine Distribution Agreement with Grovet in Europe
Via ACCESSWIRE

Performance

YTD
-25.65%
-25.65%
1 Month
+12.01%
+12.01%
3 Month
-4.83%
-4.83%
6 Month
-1.64%
-1.64%
1 Year
-15.85%
-15.85%

More News

Read More
Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota
Via ACCESSWIRE
Zomedica Secures CE Mark for TRUVIEWTM Digital Microscope & Telepathology System, Expanding Global Market Opportunities
Via ACCESSWIRE
Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product
Via ACCESSWIRE
Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System
Via ACCESSWIRE
More Than $9M Bet On Nerdy? Check Out These 3 Penny Stocks Executives Are Aggressively Buying
Via Benzinga
Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference
Via ACCESSWIRE
ZOM Stock Earnings: Zomedica Misses Revenue for Q2 2024
Via InvestorPlace
Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth
Via ACCESSWIRE
Zomedica Taps Into Costa Rica With Strategic Partnership With SIRE Veterinario
Via Benzinga
Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America
Via ACCESSWIRE
Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET
Via ACCESSWIRE
The United States Eventing Association Names Zomedica’s PulseVet(R) as the Official Shock Wave of the USEA
Via ACCESSWIRE
Zomedica Expands Global Reach Through Strategic Alliance with Leader Healthcare Group for Sales Expansion in Key International Markets
Via ACCESSWIRE
7 ‘Lottery Ticket Stocks’ That Could Turn $1K into $10K
Via InvestorPlace
US Equestrian Names Zomedica’s PulseVet System as the Official Shock Wave Therapy of US Equestrian Team Veterinarians
Via ACCESSWIRE
Zomedica Expands TRUFORMA Addressable Market with Launch of Equine Cortisol Assay for the Platform
Via ACCESSWIRE
Zomedica Expands Market Opportunity for the TRUFORMA Point-of-Care Diagnostic Platform by Securing CE Mark
Via ACCESSWIRE
$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
The 3 Most Undervalued Penny Stocks to Buy in June 2024
Via InvestorPlace
Sidoti Events, LLC's Virtual June Small-Cap Conference
Via ACCESSWIRE
Zomedica to Present at the Sidoti Small Cap Conference June 12, 2024
Via ACCESSWIRE
Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference
Via ACCESSWIRE
Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.